

Claim 6 (Canceled).

7. (Currently amended) A pharmaceutical composition comprising at least one peptide according to claim 1 ~~any of claims 1 through 6~~ and a pharmaceutically acceptable carrier.
8. (Previously presented) The pharmaceutical composition according to claim 7 further comprising an immunostimulatory molecule.
9. (Previously presented) The pharmaceutical composition according to claim 8 wherein the immunostimulatory molecule is selected from the group consisting of IL-2, B7.1, B7.2, ICAM-1, LFA-3, CD72, GM-CSF, TNF α , INF γ , IL-12, IL-6 and combinations thereof.
10. (Previously presented) The pharmaceutical composition according to claim 7 further comprising an HLA class I molecule or a cell expressing an HLA class I molecule.
11. (Previously presented) The pharmaceutical composition according to claim 7 further comprising a chemotherapeutic drug, antibiotic, antiviral drug, antifungal drug, or cyclophosphamide.
12. (Previously presented) The pharmaceutical composition according to claim 7 further comprising an adjuvant.
13. (Previously presented) The pharmaceutical composition according to claim 12 wherein the adjuvant is selected from the group consisting of alum, incomplete Freund's adjuvant, QS21, and Ribi DetoxTM.
14. (Currently amended) A peptide-immunoglobulin conjugate comprising the peptide according to claim 1 ~~any of claims 1 through 6~~ and an immunoglobulin molecule.
15. (Previously presented) The pharmaceutical composition according to claim 7 wherein the peptide is incorporated into a liposome.
16. (Previously presented) A peptide-carrier molecule conjugate comprising the peptide according to claim 1 conjugated to a carrier molecule.
17. (Previously presented) The peptide-carrier molecule conjugate according to claim 16 wherein the carrier molecule is selected from the group consisting of influenza peptide, tetanus

toxoid, tetanus toxoid-CD4 epitope, Pseudomonas exotoxin A, poly-L-lysine, a lipid tail and an endoplasmic reticulum signal sequence.

18. (Previously presented) A kit comprising the agonist peptide according to claim 1 and a vector comprising a nucleic acid sequence encoding CEA.

19. (Previously presented) The kit according to claim 18 further comprising an immunostimulatory molecule.

Claims 20-45 (Canceled).

46. (Previously presented) The pharmaceutical composition according to claim 10, wherein the HLA Class I molecule is HLA-A2.

47. (Previously presented) The kit according to claim 18, wherein the encoded CEA comprises an epitope YLSGANLN (SEQ ID NO:1).

48. (Previously presented) The kit according to claim 19, wherein the immunostimulatory molecule is GM-CSF.